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In recent years it has become increasingly important for toxicology laboratories to 
understand the metabolism of Novel Psychoactive Substances (NPS) to facilitate 
their identification in forensic and medical contexts. Abuse of the potent 
hallucinogenic NBOMe-type NPS, colloquially known as “N-bomb” has become 
prevalent in recent years. There are many different forms of these synthetic 
phenethylamines including 25I, 25C and 25B-NBOMe. The focus of this research is 
to establish optimised in vitro methods for the formation of 25H-NBOMe 
metabolites and liquid chromatography-mass spectrometry techniques to identify 
them. It was hypothesised that the metabolic transformations undergone by 25H-
NBOMe would parallel those previously reported for other NBOMe variants.  
25H-NBOMe was incubated with human S9 liver preparation; a liver post-
mitochondrial supernatant, thus simulating in vivo xenobiotic metabolism. The 
metabolic products were extracted, and the chromatographic profile was generated 
via LC-QTOF-MS. Demethylated and hydroxylated products were identified 
resulting from Phase I biotransformation. In incubation mixtures containing acetyl 
CoA, UDP glucuronic acid and phosphoadenosine phosphosulfate, the presence of 
conjugates generated by the Phase II processes, acetylation, glucuronidation, and 
sulfation were explored. Neither glucuronides nor sulfate or acetyl conjugates were 
detected. Potential sites on the NBOMe molecule for demethylation, hydroxylation 











1.1 Introduction to NBOMe and rationale for the study  
 
Psychoactive substances, like all other drugs and xenobiotics, are prevalent in our 
society. Xenobiotics are substances foreign to the body, required to be processed and 
eliminated. As the name suggests, psychoactive substances are compounds which by 
binding to various receptors in the brain, generate a variety of different mental and 
physical effects resulting in alterations to brain function(1). Such substances are 
generally prohibited and used for recreation, including those commonly known as 
cannabis, LSD, cocaine and ecstasy. These drugs are taken recreationally to 
experience side effects such as euphoria and hallucinations. Deleterious side effects 
include nausea, coronary arrhythmia and paranoia, subject to the type of drug, dose 
and frequency of use(2). There are many different psychoactive drugs, many different 
forms of the same drugs, and many ways of ingesting them to experience maximum 
effects. The desire for the perceived positive effects means there will always be a 
demand for such substances. 
Novel Psychoactive Substances (NPS) are classified as substances that are synthetic 
derivatives of psychoactive compounds which are already illegal and controlled(3). 
The production of such derivatives involves a vast range of chemical modifications. 
Most often this is the substitution of one functional group for another, or a structural 
re-arrangement to create an isomer. It therefore follows that this specific compound, 
of altered structure and chemical composition, is not specifically illegal.  
Consequently, they are used recreationally to achieve the same or similar side effects 
as their illegal forms. This perpetuates the occurrence of what is termed “legal 
highs”. As the use of NPS increases, so do cases of intoxication and overdose and 
the risk of long term harm, as with any other drug. The problem with NPS is that the 
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appropriate bodies (forensic laboratories and hospitals) cannot accurately test for or 
identify these drugs. This can hinder toxicological assessment and treatment(3). 
Hence, it is important that assays are developed to identify NPS and their metabolites 
such that reference standards can be developed and quantification achieved for use in 
forensic, coronial and criminal investigations. Not only does such work provide a 
means of appropriate treatment to be administered in cases of overdose, it provides 
the necessary information to enable the relevant bodies to enact legislation to 
prohibit the drug, reducing its danger to public health(4).     
One such NPS which has recently entered the illegal drug market is the NBOMe 
type. Colloquially known as “N-bomb”, NBOMe-type drugs are potent 
hallucinogens. The first of these was synthesised in 2003 by the German Chemist 
Ralf Heim, and was further studied by other chemists such as David Nichols, who 
determined the structure with the use of radioactive labelling(5). NBOMe can be 
taken in the form of a tablet, a liquid, powder, or from blotting paper.  By 2010, its 
recreational use had become significant, assisted by its availability online at low 
cost, as an alternative to the illegal hallucinogen LSD. Worldwide, abusers began to 
present with symptoms of drug intoxication including convulsions, hyperthermia, 
tachycardia and renal failure(6). These patients reported use of “N-bomb”, and 
analysis of urine samples confirmed the presence of a particular form of NBOMe, 
the same as was found in the early investigative work of Nichols(5).    
Nichols found drugs of the NBOMe type to be a synthetic, modified form of the 
naturally occurring class of organic compound known as phenethylamines, present in 
some plant species. An example is the hallucinogenic alkaloid mescaline, found in 
the peyote cactus(7). Modified phenethylamines appear to be the most numerous 
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among NPS, their structure characterised by substitution of the functional groups at a 
variety of different positions to confer different properties and potencies (8). NBOMe 
is an N-benzyl derivative of the structure and the different substitutions of NBOMe 
will, most likely, exert effects of different magnitude(9).  
For example, 25B-NBOMe and 25I-NBOMe are both NBOMe- type drugs and share 
a common basic structure. Both 25B-NBOMe (4-bromo-2,5-dimethoxy-β-
phenethylamine), and 25I-NBOMe (4-iodo-2,5-dimethoxy-β-phenethylamine) 
contain a 2,5-dimethoxy-β-phenethylamine moiety (9). In 25B-NBOMe and 25I-
NBOMe an amino group is replaced by bromine and iodine, respectively(9).  
Figure 1.1 displays the structures of four NBOMe derivatives. The arrows indicate 
the various functional groups that create the unique derivative. The circle around the 
carbon on the 25H-NBOMe structure shows the presence of the hydrogen, which 













As previously mentioned, drugs of the NBOMe type are taken recreationally for their 
hallucinogenic effects. Phenethylamines are 5-HT2A (5-hyrdoxytryptamine, subtype 
2A serotonin) receptor agonists, meaning binding of such compounds increases the 
activity of the neurotransmitter serotonin. Consequently, the mood, behaviour and 
memory of the user is altered. Additionally, hallucinations are induced when 5-HT2A 
receptors in the cortex of the brain are stimulated, encouraging the use of the drug 
for recreational purposes(11). Modifications of phenethylamines to produce an 
NBOMe derivative can generate a product which exhibits a higher affinity for 5-
HT2A receptors. Consequently, NBOMe drugs often display  increased potency and 
more pronounced psychoactive effects at lower doses(12).   
Elucidation of drug metabolites is a key process in preliminary investigation of NPS.  
It is often necessary to identify the metabolites of a drug additionally to the parent 
compound because, in most cases, time will have elapsed since ingestion and, as a 
consequence, metabolism will have occurred. Depending on the toxicokinetic 
properties of the drug in question, and the time elapsed since ingestion, the parent 
compound may be undetectable in body fluids(13).                                                                                                                         
1.2 Legislation surrounding Novel Psychoactive Substances   
It is important to ensure that the legislation surrounding their availability, use and the 
consequences of NPS use are designed to facilitate the protection of the public. The 
aim of  legislation is to criminalise the manufacture, possession with intent to sell, 
possession with intent to use, importation, exportation, and use of psychoactive 
substances(14). Currently, European countries, and in particular, the UK, have enacted 
the most comprehensive laws pertaining to the control of NPS(15).    
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Globally, the use of NPS has increased markedly since 2013. According to the 
United Nations Office on Drugs and Crime (UNODC), 94 countries reported the use 
of 348 different NPS between 2008 and 2013. In 2015 alone, 643 new NPS were 
reported, encompassing 101 countries(16). These included a diverse range of 
substances including psychostimulants, opioids and cannabinoids. Different 
countries, having identified the various NPS via different means, have thus enacted 
laws prohibiting their use. It follows that with every new psychoactive drug, there 
may need to be an amendment to the laws prohibiting its possession or use. 
The criminalisation of a specific drug requires data collection. Initially, this may be 
achieved by seizure of the drug itself, or may be derived from its detection in a 
biological matrix such as blood or urine. It follows that the laboratory performing the 
analysis must have access to and be capable of performing an assay which accurately 
identifies the compound. Compound identification and characterisation is essential 
knowledge because the structure and mechanism of drug action is required to be 
known before the substance can be rendered illegal and penalties imposed for its 
possession and use (15).       
For laws to be enacted, there must be evidence of the molecular mode of 
psychoactive action(16). However, the rapid proliferation of novel drugs, as 
previously discussed, limits the ability of laboratories to derive assays for their 
detection in a timely manner because appropriate methods, standards and reagents 
may not be available(15). Moreover, once an assay has been developed for a new 
drug, and laws enacted to make it illegal, it is possible that a different variant has 
emerged for which the lab has no validated assay for its detection or quantification.  
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The UNDOC evaluated the efficacy of laws enacted in those countries in which NPS 
appear to be most prevalent. Laws in some parts of the world are generic; they 
prohibit substances and any variations or derivatives which have the same core 
molecular structure(16). This negates the need to individually and specifically name 
and outlaw a drug; advantageous because it automatically renders illegal a derivative 
of the parent drug. However, it can also be argued that this mode of law making is 
irresponsible because it automatically prohibits the use of a substance which,  in 
comparison to the original form, may be more therapeutically useful(16).    
Alternatively, it is possible to prohibit drugs based on their biochemical activity 
rather than on the basis of their structure.  For example, in the USA the “Synthetic 
Drug Abuse Prevention Act” of 2012, specifically prohibits any “cannabimimetic” 
agent, that functions as a cannabinoid type 1 receptor (CB1) agonist(16). However, 
the disadvantage of this method is the potential criminalisation of therapeutic agents 
with the same biochemical mode of action.   
In many countries, drugs are criminalised by being specifically listed in the 
legislation. For example, in  2011, Brazil specifically listed the synthetic 
amphetamine “Mephedrone” as illegal under their psychoactive substances 
act(16).This approach requires that any new substance be uniquely identified, its 
structure defined and its mechanism of action elucidated before it can be outlawed. 
This is not an effective method of criminalisation because it requires constant 
renewal of legislation. Given the nature of NPS, it is not possible to generate and 
validate assays rapidly enough to ensure that each new variant is specifically 
included in the law. This approach, however, may be applicable in countries with a 
small NPS market where it is more feasible to identify variants in legislation(16).  
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To protect the public from “legal highs” in 2015 the Psychoactive Substances Bill in 
the UK was introduced, in compliance with the Human Rights Act of 1998(17). The 
bill was drafted in a way to include not only substances already known, but those yet 
to be identified or yet to be generated(17). This law criminalised the possession of and 
intent to supply, import or export psychoactive substances to be an offence with a 
possible maximum penalty of seven years imprisonment. It defined a psychoactive 
substance as any consumable substance capable of producing effects of a 
psychoactive nature. Additionally, the bill authorised law-enforcement officers to 
enter premises, search for, and seize suspicious material. Importantly, it also allows 
for seized substances to be retained. Consequently, when no longer required as 
evidence, they could be studied so as to enhance the knowledge of NPS currently 
circulating in the community(17).  
Prior to 2015 laws in the UK banned various phenylethylamine derivatives, however, 
N-benzyl substitutions were not explicitly included in the legislation. As NBOMes 
belong in this category, they were not specifically rendered illegal. In 2013, given 
the increased incidence of use and intoxication by 2C-NBOMe and 2I-NBOMe, 
swift action was taken by the British government in an attempt to limit the use of 
NBOMe(18). A temporary class order was declared, immediately prohibiting sale, 
import and production of N-benzyl substituted phenethylamines, N-benzyl 
substitution being the chemical modification characteristic of NBOMe-type drugs.  
However, it did not restrict personal use(18). Temporary class orders are employed 
when immediate action is required. They take effect within days, and are valid for a 
maximum of twelve months, during which time a Bill can be drafted to ban the drug 
permanently.    
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The lack of legislation specifically pertaining to NBOMe drugs is responsible, in 
part, for the rapid increase in their production and use in recent years. In the early 
2000s the N-benzyl phenethylamine derivatives (NBOMe) became more prevalent at 
events such as music festivals. In 2013 NBOMe was identified as a major public 
health concern due to the report of many more derivatives and dangerous 
intoxications(19).  
1.3 Novel Psychoactive substances: A problem faced by forensic laboratories 
To identify and quantify a substance, a reference standard and an authentic sample of 
the substance are required. If the drug is novel, it is highly likely that a reference 
standard is not available, and established methodology and instrument 
standardisation procedures are not yet in place.    
Analyte biotransformation is another factor that must be taken into consideration. 
Psychoactive substances are active in biological matrices and are, therefore, subject 
to metabolic modification. The metabolic transformations that xenobiotics undergo 
in vivo often direct the analytical methods employed to detect them in body fluids. 
The parent drug may have been converted into a range of metabolites, some of which 
may have already been conjugated with other compounds in preparation for 
excretion. NBOMe drugs are ingested in very small amounts of approximately 50-
100μg whereas other psychoactive drugs are consumed in amounts as high as 
200μg(20). This is reflected in the fact as little as 50μg of NBOMe can cause 
psychosis, whereas much higher doses of other drugs, being 100-200μg, is 
required(18), (20). Therefore, detection of parent NBOMe is already more challenging 
than the detection of drugs taken at a higher dose. NBOMe is biotransformed into 
even smaller amounts of a range of metabolites such that the parent drug is often 
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present merely in trace amounts in blood or urine. In such cases the parent drug may 
be below the limit of detection.   
Given that biotransformation has taken place, it is likely that the concentration of 
metabolites in the plasma or urine will be higher than that of the parent drug, making 
it imperative that research is undertaken on such drugs in order to identify  their 
metabolites and to develop sensitive, reliable and validated assays to detect them(12).  
It is often via toxicological analysis of patient samples that new derivatives of novel 
drugs are discovered. Initially, tests are performed using standards of previously 
known variants, or with a standard of the parent drug. For example, Laskowski et al. 
(2015), using an NBOMe reference standard, identified a new derivative(5). Serum 
and urine samples were taken from a 16-year-old girl presenting with signs of 
NBOMe intoxication including visual hallucinations, slurred speech and loss of 
muscle control. The patient admitted to self-administration of a substance called 
“25I” via blotter paper at a music festival(5).   
Following liquid extraction procedures, the extract was analysed by High 
Performance Liquid Chromatography and tandem Mass Spectrometry 
(HPLC/MS/MS). An internal standard 25-NBOMe-d3 was used. Comparison of the 
resultant chromatograms, that of the reference standard and of the test sample, 
revealed the presence of chlorine in the test sample(5). It can be seen from Figure 1.3 
that the peaks in the 25-NBOMe-d3 and test chromatograms have different retention 
times, 9.42 and 7.38 minutes respectively. 
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 Figure 1.3 Chromatographic separation of 25B and 25I-NBOMe-d3 in the patient’s 
serum sample, displaying the different retention times of each compound, assisting 
in the identification of a new previously unknown derivative.   
The analysis revealed that the substance in the test sample contained a chlorine N-
Benzyl substitution, and can thus be termed 25C-NBOMe; a new NBOMe 
derivative(5). Confirmation of the structure of new derivative resulted from 
interpretation of the mass spectrum associated with the specific peak identified in the 
chromatogram.   
1.4 Drug metabolism in the human body: an overview   
An understanding of the metabolic fate of xenobiotics and the molecular 
mechanisms via which these biotransformations occur is central to this project. 
Foreign compounds such as NBOMe are metabolised by liver enzymes in two major 
phases; termed Phase I and Phase II reactions. Phase I reactions are designed to 
modify the xenobiotic as a means of reducing its biological activity. These reactions 
include oxidations, reduction, hydroxylation, deamination, decarboxylation and 
hydrolysis. These reactions not only (usually) reduce the biological activity of the 
parent compound, but prepare it for entry into Phase II reactions by providing the 
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compound with a conjugating site for molecules involved in the Phase II 
reactions(21). For example, the hydroxyl group added to the compound in Phase I 
hydroxylation, provides a site for the enzyme-catalysed addition of a conjugating 
compound in a Phase II reaction.   
Phase II reactions involve the conjugation of the xenobiotic, often, but not always, 
after Phase I modification, with another compound which renders it soluble in bile or 
urine so that it can be readily excreted from the body (21).There are two types of 
Phase II reactions. The type 1 Phase II reactions involve the activation of the 
conjugating compound prior to its conjugation with the deactivated xenobiotic. In 
sulphation for example, sulphate is converted to its active form phosphoadenosine 
phosphosulphate (PAPS), while glucuronidation is the conversion of glucuronic acid 
to active UDP glucuronic acid. Similarly, the conversion of acetate to the active 
thiolester acetyl CoA, allows for the drug to be acetylated in a type 1 Phase II 
reaction(22).  
Type 2 Phase II reactions, on the other hand, involve activation of the xenobiotic 
itself, prior to conjugation. For example, the activated xenobiotic may be conjugated 
with glutathione to generate a urine-soluble mercapturic acid.  Following Phase II 
reactions, the solubilised xenobiotic can then be excreted from the body in either 
urine or faeces(22).   
1.5 Phase I metabolism  
Cytochrome P450 enzymes (CYPs) are the enzymes predominantly expressed in 
hepatocytes and are principally involved in Phase I reactions. Bound to the surface of 
the endoplasmic reticulum, CYPs catalyse approximately 75% of the interactions 
that occur between xenobiotics and human cells(23). CYPs are the group of enzymes 
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that catalyse oxidative and hydroxylation reactions. They are feature a haeme group 
bound to a polypeptide chain and are classified into three “families”; CYP1, CYP2 
and CYP3(24). Additionally, CYPs catalyse demethylation involving sulphur, 
nitrogen or oxygen atoms; S-, N- or O-demethylation respectively. In the case of O-
demethylation, this generates an hydroxyl group which provides a conjugating site 
for the Phase II reactions. CYPs require both oxidising and reducing power for their 
catalytic activity, provided by molecular oxygen and NADPH, respectively. For this 
reason, CYPs are also referred to as “mixed function oxidases”(25). The “P450” 
assignment to the name of these cytochromes refers to the wavelength (450nm) at 
which these cytochromes exhibit maximum spectrophotometric absorption 
(450nm)(26).     
Caspar et al. (2017) identified some of the CYPs involved in the metabolism of 25B-
NBOMe. The authors found that CYPs CYP1A2, CYP2B6, CYP3A4 and CYP3A5 
were capable of cleaving an N-demethoxybenzyl group from the parent drug and that 
CYP1A2, CYP2C9, CYP2C19 and CYP3A4 catalysed O-demethylation of the 
compound (12). They concluded from LC-HR-MS/MS analysis that O-demethylation 
and hydroxylation were the main Phase I biotransformation reactions that occurred. 
It was reported that 25C and 25I-NBOMe were similarly metabolised and it can be 
inferred that 25H-NBOMe is likely to undergo similar metabolic transformations 
catalysed by  the same or closely related CYP isoenzymes(12).  
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The key Phase I reactions explored in this investigation were demethylation and 
hydroxylation. Demethylation is the enzyme-mediated removal of CH3 from a 
compound, shown in Figure 1.5.1 for 25B-NBOMe(27).  
 
Figure 1.5.1 Example of the Phase I process of demethylation for 25B-NBOMe.  
Hydroxylation is the enzyme mediated addition of an OH group to a compound, as 
shown in Figure 1.5.2 for 25H-NBOMe(27).  
 
Figure 1.5.2 Example of the Phase I process of hydroxylation for 25B-NBOMe. 
1.6 Phase II metabolism 
Additionally, Wohlfarth et al. (2016) found that when 25C and 25I-NBOMe were 
incubated with human hepatocytes, acetylation, sulphation and glucuronidation 
where the main Phase II reactions to occur. It is speculated that these Phase II 
reactions will also be characteristic of 25H-NBOMe metabolism(13). Phase II 
metabolism therefore involves activation of either the conjugating compound or the 
xenobiotic itself, followed by enzyme-catalysed conjugation of the parent 
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compound, or a less-biologically active Phase I metabolite. Most commonly, this 
generates a glucuronide, acetyl or sulphate derivative. Acetylation, glucuronidation 
and sulphation are all type 1 Phase II reactions, which require activation of the 
conjugating compound prior to conjugation.  
a. Conjugation with Acetate 
Acetate is activated as shown in Figure 1.6.1(28): 
 
Figure 1.6.1 Activation of acetate to Acetyl CoA preceding the process of 
acetylation.   
Through the action of acetyl CoA synthetase, active acetyl CoA is produced which 
then donates its acetyl group to the xenobiotic in a type 1 Phase II conjugation 
reaction(28).  
b. Conjugation with Glucuronic acid  
As illustrated in Figure 1.6.2, UDP glucose pyrophosphorylase is responsible for the 
synthesis of UDP glucose from glucose-1-phosphate. The UDP glucose generated is 
oxidised with NADP to form active UDP glucuronic acid and NADPH, the reaction 















Figure 1.6.2 The generation of active UDP glucuronic acid prior to Phase II 
glucuronidation.  
 
The Phase I metabolite is then conjugated with glucuronic acid to form a glucuronide 
which is excreted.  
c. Conjugation with Sulphate  
Figure 1.6.3 depicts the formation of “active sulphate” (PAPS), which precedes 
sulphate conjugation in a type 1 Phase II reaction. Adenosine and phosphate sourced 
from ATP are joined to sulphate (SO4
2-) to from adenosine phosphosulphate. 
Adenosine phosphosulphate is then phosphorylated by ATP to produce 
phosphoadenosine phosphosulphate, which provides the source of the sulphate for 















Figure 1.6.3 The activation of PAPS required before conjugation of the xenobiotic 
with sulphate.  
Phase II biotransformation may further reduce the bioactivity of the Phase I 
xenobiotic metabolite, and the modification alters its polarity making it more soluble 
in either urine or bile which aids its excretion from the body.   
1.7 NBOMe-type drugs as hallucinogens        
It is reasonable to infer the NBOMe drugs are hallucinogens firstly because they are 
structurally similar to LSD, a known hallucinogen, and secondly, because, 
phenethylamines are known central nervous system stimulants. Importantly, some 
users, having experienced hallucinations after reporting LSD use, were actually 
found to have taken NBOMe(13). It is reasonable to conclude that NBOMe is 
psychotropic in some way (affecting the brain and one’s mental state). If this is 
accepted, the next step is to specify the biochemical mechanism by which this 
occurs.        
Rickli et al. (2015) investigated the binding affinities and receptor interaction 
profiles of a number of a number of 2C (psychedelic phenethylamines with a 
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methoxy group on the 2 and 5 position of the benzene ring) and NBOMe-type drugs. 
A number of 2C drugs and their corresponding NBOMe derivatives, along with LSD 
and mescaline (for corroboration and comparison) were incubated with human cells 
which had been transfected with various known drug transporters and receptors 
known to produce psychotropic effects(31).  To evaluate the activity of the serotonin 
5-HT2A receptor in the presence of the various xenobiotics, embryonic fibroblasts 
(NIH-3T3) cells were incubated with the test substance and the fluorescence 
subsequently measured, derived as the receptors were tagged with a fluorescent 
compound(31).    
The activity of the serotonin 5-HT2B receptor was investigated using HEK 293 
(human embryonic kidney cells) in a similar manner(31). In general, it was found that 
all of the test substances bound to 5-HT2A and 5-HT2C receptors with high affinity. 
Importantly, the N-2-methoxybenzyl substitution which generates an NBOMe, 
resulted in a 26 and 14-fold increase in binding affinity for these receptors 
respectively. This is approximately 8.4 times higher than that resulting from LSD(31). 
It was also found that, like LSD, NBOMe drugs exhibited high affinity for 
adrenergic α1A receptors. This correlates with the cardiovascular side effects reported 
by users including tachycardia and other adrenergic-like effects(31).  The nature of the 
interaction between NBOMe and the serotonin 5-HT2A receptors is unknown and its 
mode of action via such an interaction can only be inferred. It is important to note 
that though this study concluded that NBOMe drugs bind with increased affinity to 
5-HT2A receptors, studies have not been conducted to confirm whether or not this 




 Serotonin receptors are named because of their capacity to bind,5-
hydroxytryptamine (5-HT). Serotonin (5-hydroxytryptamine) is a monoamine 
neurotransmitter. 5-HT2A receptors are predominantly located on the dendrites of 
nerve cells in the cortex of the brain (32).  Physiologically, serotonin controls 
functions such as appetite, thermoregulation, mood and various cognitive processes. 
Additionally, activation of the 5-HT2A receptor has been implicated in stress-
mediated pathophysiological responses (33).  Release of serotonin is known to have a 
role in learning and cognition, and increased levels are known to distort perception, 
creating hallucinations. 
The mechanism of 5-HT2A activation involves interaction with a G-protein, the 
closing of potassium ion channels and consequential depolarisation of the axon (32). 
The increased excitability of the neuron results in increased serotonin release. This 
can generate hallucinations due to the wide distribution of the receptors on post-
synaptic dendrites in the central nervous system(34).     
1.8 The analysis of NPS: Evolution and evaluation of methods over time 
The development of sensitive, optimised assays to identify and quantify in body 
fluids, not only parent drugs of the NPS class, but also their metabolites, is essential 
from a medical and forensic perspective. One of the early methods used to identify 
the presence of NPS employed Gas Chromatography-Mass Spectrometry (GCMS). 
In 2004 Staack and Maurer published the method they employed to detect the 
amphetamine-derived novel drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP) 
and its metabolites in rat urine. They found the drug and its metabolites to be higher 
in concentration and to persist for longer in the urine than in the plasma. This early 
study aimed at the detection of NPS was an important advancement(35).  
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The components of the incubation mixtures (containing MDBP and its metabolites, 
both acetylated or methylated) were separated by gas chromatography. The 
ionisation methods used were EI (electron impact ionisation) followed by PICI 
(positive ion chemical ionisation). Comparison of the resultant mass spectra with 
those on the reference database confirmed the identity of the ions in the spectra(35). 
The structure of the various metabolites was inferred from the fragmentation pattern 
of the ions.  
It was concluded that MDBP is metabolised via demethylation followed by 
glucuronidation and sulfation to render the metabolites urine soluble. This study 
established protocols for the detection and identification of other novel drugs in 
urine.(35). Consequently, a similar approach was employed by Caspar et al. (2017) to 
detect and identify 25B and 25C-NBOMe and their metabolites in rat and human 
urine(12).     
After the administration of the drugs to male Wistar rats, urine was collected for the 
next 24 hours. A human urine sample was also obtained antemortem from a 
suspected case of 2C-B-NBOMe ingestion. Sample preparation involved pH 
adjustment with acetic acid and incubation with glucuronidase and arylsulfatase to 
hydrolyse potential conjugates. A series of elution and evaporation steps was 
performed, and a 5μL aliquot was analysed using LC-HR-MS/MS(12). 
Identification of the metabolites of 25C and 25B-NBOMe metabolites was achieved 
via interpretation of the high resolution MSMS fragmentation patterns for each drug. 
The human sample was similarly treated and analysed. The analysis confirmed that 
fragment ions resulted from cleavage of the NBOMe portion of the drug, rather than 
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from cleavage of the 2C structure. The fragmentation patters were found to be 
similar to that of  25I-NBOMe (12).    
This analytical approach appears to be suitable for the detection of NBOMe 
metabolites and can provide information on the biotransformations undergone in 
vivo. However, as the majority of xenobiotic metabolism occurs in the liver, more 
direct information on the Phase I and Phase II reactions involved in the metabolism 
can be obtained from ex vivo studies using hepatocytes or from in vitro studies using 
microsomal preparations.    
Logically, the former approach is preferable as it more closely approximates in vivo 
conditions. However, in most laboratories it is not feasible to use hepatocytes 
directly. This is because the maintenance of hepatocyte cell cultures requires 
expensive equipment and nutritional media. Additionally, the expertise required to 
maintain cell culture growth and analysis requires expertise not accessible to every 
laboratory(11). Consequently, in vitro approaches using liver microsomes are often 
favoured. 
Liver microsomes are fragments of endoplasmic reticulum to which are bound 
enzymes involved in the Phase I metabolism of xenobiotics. Of significance are the 
CYPs, Flavin-containing monooxygenases (FMOs) and UDP-
glucuronosyltransferases (UGTs)(4) They are obtained and isolated from hepatocytes 
in a series of homogenisation and centrifugation steps. Human Liver Microsome 
preparations (HLMs) do not contain any cytosol, therefore, in incubation mixtures 
where HLMs are the biological matrix of choice, the mixtures need to be 
supplemented with cytosolic enzymes known to be involved in the enzymatic 
processes being investigated. Incubation of  these preparations with a xenobiotic of 
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interest in vitro, followed by analysis of the products via LC or GC and MS, 
provides a means by which metabolites can be characterised(4).    
In 2016, Nielson studied the metabolism of 25I-NBOMe by incubating the drug with 
human liver microsomal preparations in the presence of NADPH. Supernatants 
obtained from the incubations were then analysed by LCMS. Interpretation of the 
resultant mass spectra allowed identification of metabolites produced by  O-
demethylation, N-dealkylation and dehydrogenation(8).      
A potentially more accurate and broad-spectrum approach to the investigation of 
xenobiotic metabolism in the liver is to incubate the drug in question, in vitro, with 
S9 liver preparations. This preparation is similarly obtained via homogenisation and 
centrifugation of hepatocytes at 9000g (hence the name “S9”)(4). These preparations 
are also referred to as “post-mitochondrial supernatants” because they do not contain 
mitochondria, these having been lysed and released in the homogenisation process 
and removed by low speed centrifugation. S9 preparations contain both hepatocyte 
microsomes and cytosol (unlike microsomes which do not contain cytosolic 
enzymes). Consequently, S9 preparations not only contains the microsomal 
monooxygenases associated with Phase I biotransformation, but the soluble, 
cytoplasmic enzymes involved in Phase II conjugation reactions. S9, therefore, is 
more representative of the hepatic enzymes in drug metabolism(4). Figure 1.8 




Figure 1.8. How S9 and HLMs are derived from hepatocytes(36).   
Otto et al. (2008) designed an assay to investigate the potential hepatotoxicity of the 
non-steroidal anti-inflammatory drug diclofenac, and the antibiotic, minocycline. S9 
liver preparations and an NADPH regenerating system were employed to maximise 
the in vitro yield of Phase I metabolites(37). Being that microsomal monooxygenases 
require the supply of a reductant, in the form of NADPH, and an oxidant, in the form 
of molecular oxygen, the incubation mixtures were supplemented with NADP+ and 
glucose-6-phosphate. During the course of the incubation, glucose-6-phosphate 
dehydrogenase, present in the cytosolic component of the S9 preparations, converts 
glucose-6-phosphate dehydrogenase to 6-phosphoglucono--lactone, with the 
concomitant production of NADPH from NADP+. This NADPH regeneration 
process provides a constant supply of the reducing power required for Phase I 
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monooxygenases such as the CYP group of isoenzymes(37). Following further 
refinement, the incubation mixtures were analysed by TSQ Quantum Ultra AM 
quadrupole mass spectrometry to identify the metabolites(37).    
The use of human S9 preparations to investigate xenobiotic metabolism in vitro is 
preferable to in vivo studies in rats because S9 preparations are a commercially 
available product, negating the requirement for animal ethics approval. Moreover, 
differences in metabolism exist between species, and it is clearly not possible to 
conduct in vivo experiments on humans for ethical reasons.    
1.9 Liquid Chromatography-Quadrupole Time of Flight -Mass Spectrometry 
(LC-QTOF-MS)       
In this study of the in vitro metabolism of 25H-NBOMe, LC-QTOF-MS will be used 
to separate and identify the metabolic products generated in the incubation mixtures. 
The schematic shown in Figure 1.9.1 summarises the sequence of events that will be 
applied to separate the components of the mixture according to their differential 
affinities for the liquid and stationary phases. In this process, the separation depends 
on differences in the molecular size and polarity on the compounds present, and is 
also influenced by the type of column used(38). To identify the compounds present, 
each is injected into the ionisation chamber of the mass spectrometer where the 
chosen ion source bombards it with high energy molecules, such as electrons, 










   
   
Figure 1.9.1 The process of LC-QTOF-MS resulting in the generation of a mass 
spectrum which is used to identify compounds.  
 
The quadrupole time of flight mass analyser filters the ions according to velocity. 
“Time of Flight” refers to the fact that the m/z (mass to charge ratio) of each ion is 
determined according to the time taken for it to reach the detector. The quadrupole 
mass filter is one of the most common and accurate mass analysers. It consists of 
four metal cylinders acting as electrodes(39). A radio frequency is applied to the rods, 
and the ions from the samples travel in the space between them. The trajectory of the 
ions is influenced by the particular current applied. Being that ions of different 
masses travel through the mass analyser at different velocities, each ion is conveyed 
through the quadrupole and thus reaches the detector at a unique time, facilitating its 
identification (39).       
The mass spectrometric analysis is complete once all ions derived from the 
fragmentation of the compound have reached the detector and the mass spectral 
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fragmentation pattern has been generated. The mass spectrum is a plot of the 
abundance of a particular ion (y-axis) versus m/z (x-axis). The mass spectrum, which 
depicts the unique fragmentation pattern of the analyte, can then be used to deduce 
the molecular structure of the compound, or can be identified by comparing the 
spectra obtained with those derived from compounds of known identity.  
The use of tandem mass spectrometry aids high resolution analysis and is commonly 
referred to as “MSMS”. In tandem mass spectrometry, ions are firstly formed by the 
ion source and separated by m/z (MS1). Precursor ions are then selected and the 
fragment ions (also referred to as product ions) are created via the collision of ions in 
the chamber. The resulting ions are then separated and detected (MS2). Three 
different voltages are applied to the molecule in this process, universally 10V, 20V 
and 40V. Accordingly, the mass spectra obtained at each voltage will differ, 
resulting in highly sensitive detection of compounds and an ability to infer the 
structure of the compound from the mass spectra. This will be illustrated in the 
context of this study in later chapters(40).   
Additionally, a chromatogram of the components present in the incubation mixture 
can be obtained. This is a visual representation of the separation of components 
during the chromatographic process. Each peak corresponds to a particular 
compound in the mixture(41). The identification of the compounds present requires 
interpretation of three different characteristics for each peak. Firstly, each peak 
displays a retention time, which is the time taken for the compound to reach the 
detector. Retention time reflects the polarity of the compound and characterises the 
compound under the chromatographic conditions employed, which is not necessarily 
unique to the compound. Secondly, the mass of the molecular ion provides 
information as to what group or groups may have been removed from or added to the 
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parent compound during the metabolic transformations. Thirdly, interpretation of the 
MS/MS spectrum allows the location of these metabolic changes on the molecule to 
be identified(41). By comparing these characteristics against reference standards or 
library spectra, compounds can be identified and the metabolic processes involved in 
generating the compound, ascertained.  
Importantly, high resolution LC-QTOF-MS detects the m/z of compound to 4 dp. 
When comparing an experimentally obtained value, the relative acceptive criterion is 
that the m/z of the fragment found in the sample must be within 5ppm of that of the 
reference sample. This is calculated according to the following formula: 
ppm= {(measured mass-reference mass)/reference mass} x 1000 000  
Importantly, Wohlfarth et al. (2016) demonstrated that this method was applicable to 
the identification of 25C and 25I-NBOMe metabolites and the derivation of the 
structures of these metabolites(13).  
1.10 Aims     
The first aim of this study is to develop reliable, reproducible and optimised 
chromatographic techniques for the identification of 25H-NBOMe in biological 
matrices. The second aim of the study is to separate and identify, using LC-QTOF-
MS, the metabolites of 25H-NBOMe generated by the enzymatic activity of human 
S9 preparations in incubation mixtures in vitro.  
1.11 Hypothesis         
It is hypothesised that that Phase I metabolism of 25H-NBOMe will parallel that of 
25B, 25C and 25I-NBOMe and will be characterised by Phase I demethylation and 
hydroxylation. It is also hypothesised that, in corroboration with previously studied 
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NBOMes, acetylation, glucuronidation and sulfation will constitute the major Phase 






























































2.1 Incubation assays 
Chemical reagents  
Dipotassium hydrogen sulfate K2HPO4 (Sigma Aldrich)  
Potassium dihydrogen phosphate KH2PO4 (Sigma Aldrich)  
β-Nicotinamide adenine dinucleotide 2`-phosphate reduced tetrasodium salt hydrate 
NADPH (Sigma Aldrich) 
N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (25H-NBOMe, ChemCentre)  
2-(dimethylaminomethyl)-1-(3-methoxyphenyl) cyclohexanol (Tramadol, 
ChemCentre)  
1-pentyl-3-(1-naphthoyl) Indole (JWH18, ChemCentre)  
N-acetyl-para-aminophenol (Paracetamol, ChemCentre)  
Codeine (ChemCentre) 
Acetyl Coenzyme A sodium salt (Acetyl CoA, Sigma Aldrich)  
Uridine 5-diphosphoglucuronic acid trisodium salt (UDP glucuronic acid, Sigma 
Aldrich) 
Adenosine 3`-phosphate 5`-phosphosulphate lithium salt hydrate (Phosphoadenosine 
phosphosulphate, PAPS, Sigma Aldrich)  
S9 from pooled human liver microsomes 20mg protein/ml (Sigma Aldrich) divided 
into 50μl aliquots, stored in Eppendorf tubes at -80°C 
2.2 Sample extraction and reconstitution  
Chemical reagents  
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Ethyl acetate   
2.3 LC-QTOF-MS  
Instrumental details  
Agilent technologies Dual AJS ESI ion source MS Q-TOF  
Component model G6540A 
Column: ACE Excel 3micron Super C18 100 x 3.0 mm id 
2.4 Data Analysis  

















































3.1 Preparation of parent xenobiotic  
25H-NBOMe (4.288mg) was dissolved in 1mL of acetonitrile. Tramadol (2.2mg) 
and JWH18 (2.2mg) were dissolved in 1mL of acetonitrile to generate a 4.4mg/mL 
standard of tramadol plus JWH18.  These two compounds were used as the 
xenobiotic in initial incubation mixtures because the metabolites they generate are 
well documented. Consequently, they are appropriate compounds to assess the S9 
incubation conditions  
3.2 Preparation of incubation mixtures 
K2HPO4 (1.387g) and KH2PO4 (0.534g) were dissolved in 100mL of deionised 
water to generate a 100mM phosphate buffer. The pH was adjusted to 7.4 using 
KOH (to increase pH) or H3PO4 (to decrease pH) as required. NADPH (16.5mg) was 
dissolved in 100μL phosphate buffer to generate a 200mM solution.  
3.3 Phase I metabolism: Incubation of 25H-NBOMe with S9 
Buffer (169μL), NADPH (10μL) and S9 (20μL) were added. Following pre-
incubation at 37°C for 5 minutes, the reaction was commenced by the addition of 
1μL of substrate (25H-NBOMe). After mixing, the tubes were incubated for one 
hour. The incubation concentration of 25H-NBOMe was 71μM and the final volume 
of the incubation mixture was 0.200mL.  
3.4 Phase II metabolism: Incubation of 25H-NBOMe with S9 and phase II 
conjugating compounds  
Buffer (159µL), NADPH (10µL) and S9 (20µL) S9 were added. 10µL of the 
relevant conjugating compound stock solution was added prior to the addition of 
1µL of 25H-NBOMeto commence the reaction. The Conjugating compound stock 
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solutions were Acetyl CoA (2.87mg) dissolved in 5mL of buffer, UDP glucuronic 
acid (2.294mg) dissolved in 5mL of buffer, and PAPS (0.7204mg) dissolved in 2mL 
of buffer. The concentration of each in the final incubation mixture was 35.5μM.  
3.5 Sample extraction and reconstitution 
After incubation, the contents of each test tube was transferred to appropriately 
labeled Eppendorf tubes. Ethyl acetate (600µL) was added to each and vortexed for 
1 minute to mix. The sample was then centrifuged for 6 minutes to separate the 
phases and the organic layer was separated with a glass pipette and transferred into 
newly labelled test tubes. Following evaporation with nitrogen gas, 100μL of 
acetonitrile was added to each tube to reconstitute the sample.  
3.6 Incubation Mixture Protocol 
To confirm that the S9 fraction to be used in the investigation of the metabolic fate 
of 25H-NBOMe contained active enzymes involved in Phase I metabolism, 
incubations were carried out, initially, using xenobiotics for which the metabolites 
were already known. The xenobiotics chosen were JWH18 and tramadol.  
The composition of the incubation mixtures (final volume, 0.200mL) used to assess 
the capacity of the S9 fraction to generate Phase I metabolites from JWH18 and 








Table 3.6 Concentration of reagents in preliminary incubation mixtures.  
Reagent  Concentration in Incubation mixture  
Phosphate buffer  100mM 
S9 0.5mg/mL protein 
NADPH 200mM 
Xenobiotic  42μM tramadol and 31μM JWH18 
TOTAL 200μL 
 
Analysis of sample extracts was carried out via LC-QTOF-MS.  
3.7 Variable 1: Incubation time 
Incubations were carried out for 1 and 3 hours and the mixtures were then analysed 
for metabolites. 
3.8 Variable 2: Effect of enzyme concentration  
A series of incubations was carried out to evaluate the effect of enzyme 
concentration on the metabolite production. The protocol is shown in Table 3.8 
below.  




1 2 3 4 5 
 Buffer(μL) 184 179 174 169 164  
NADPH(μL) 10 10 10 10 10 
25H(μL) 1 1 1 1 1 
S9(μL) 5 10 15 20 25 
Amount of 
protein(μg) 







3.9 Variable 3: Extraction efficiency  
Extraction efficiency was evaluated using the initial incubation protocol. Extraction 
was carried out one, two, three and four times. For the sample extracted twice, 
extraction was carried out with two separate 600μL of ethyl acetate aliquots, which 
were pooled, evaporated to dryness and reconstituted. A similar protocol was 
employed three extractions 3 ethyl acetate aliquots were collected, and so on.  
The following formula was used to calculate the recovery of the parent drug: 
% Recovery= {[Response Extracted sample with analyte /Response Post extracted spiked sample]} x 
100 
The “extracted sample with analyte” was the sample that has been incubated as per 
the standard incubation protocol. The “post extracted spiked sample” was the sample 
to which the parent drug was added after the ethyl acetate was added where 100% of 
the parent drug would remain in the sample because it was not incubated and 
therefore not metabolised.  
3.10 Phase I 25H-NBOMe metabolism  
After the experimental variables had been optimised, the parameters were applied as 
shown Table 3.9 to evaluate the generation of Phase I 25H-NBOMe metabolites at 
37°C for 1 hour: 




Reagent  Incubation Mixture Concentration  
Phosphate buffer  100mM 
NADPH 200mM 





3. 11 Phase II 25H-NBOMe metabolism  
Incubation mixtures for the investigation of Phase II metabolism were carried out 
according to Table 3.11 at 37°C for 1 hour.  
Table 3.11. Incubations carried out for Phase II metabolism.  
Reagent  Incubation Mixture Concentration  























































Method development: Identification of parent Tramadol and JWH18 and 
metabolites to confirm S9 activity  
Incubation of S9 preparations with either tramadol or JHW18 using the basic 
incubation and assay protocols described in the previous chapter demonstrated that 
Phase I metabolites were generated from Tramadol and JWH18 in vitro. The 
presence of each compound was confirmed by LC-QTOF-MS analysis via the 
characteristics of retention time, a corresponding chromatogram and generation of an 
MSMS spectrum. Incubations were carried out with these two compounds to confirm 
S9 activity and the ability to detect the metabolites generated.  
 4.1. Tramadol: Identification of the parent compound   
The presence of the parent compound in the incubation mixtures was firstly 
confirmed via LC-QTOF-MS analysis of an extract of the incubation mixture. The 
data was analysed for the formula chemical formula C16H25NO2. According to the 
Agilent Mass Hunter Personal Compound Database and Library (PDCL), the 
expected mass of this parent compound (M+1) has an m/z of 264.1958. Figure 4.1 is 
the chromatogram obtained of the compound with an m/z of 264.1651, displaying 
the elution of parent tramadol at 7.6 minutes.  
 
 
Figure 4.1.1 Chromatogram derived from incubations containing tramadol.  
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The library spectra of tramadol (see Appendix) indicates that at 10V the fragment 
ion of tramadol has an of m/z 58.06512. The unfragmented parent ion has an m/z of 
264.1951 (M+1). At both 20V and 40V there is only a singular fragment present, of 
m/z 58.0651. Figure 4.1.2 displays the mass spectrum obtained from the 
chromatogram in Figure 4.1.1.  
Figure 4.1.2 Mass spectra obtained from the MSMS of tramadol.  
At 10V a fragment of both m/z 264.1950 and m/z 58.0655 is present. The fragment 
58.0655 is also present at 20V and 40V. The difference between the actual and 
theoretical m/z values is less than 5ppm (2.64) and therefore acceptable. Therefore, it 
can be concluded that this mass spectra was produced by parent Panadol.  
4.2. Demethylated tramadol 
Tramadol is known to be demethylated in metabolism, resulting in a compound with 
a chemical formula of C15H23NO2
(42). A high resolution search with this formula 
returned the chromatogram of a compound with an M+1 value of m/z 250.1790. The 
chromatogram in Figure 4.2.1 displays two peaks corresponding to this m/z value, 
with retention times of 4.97 and 5.4 minutes. The presence of two peaks suggests 
two possible sights of tramadol demethylation.  
41 
  
 Figure 4.2.1 Chromatogram of demethylated tramadol obtained from incubation 
mixtures.  
The mass spectrum in Figure 4.2.2 details the fragmentation of this compound at a 










Figure 4.2.2 Mass spectrum of demethylated tramadol indicating the loss of a 
methyl group.  
 
The spectrum displays an ion of m/z 250.1790 at 10V (M+1), 14.0161 units less than 
the parent compound, which consistent with the loss of a CH3 group. Additionally, 
the mass spectrum of the compound, obtained at 4.9 minutes, shows a fragment ion 
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of m/z 44.0498. This fragment is 14.0156 units less than the fragment of m/z 







Figure 4.2.3 Mass spectrum of demethylated tramadol for the compound eluting at 
4.9 minutes.  
Accordingly, interpretation of these spectrum allows for the fragmentation of the 
tramadol molecule to be concluded. This fragmentation is detailed in Figure 4.2.4  
Figure 4.2.4 Fragmentation of tramadol and its demethylation sites as deduced from 
the mass spectra.  
 
Figure 4.2.4 illustrates the two different tramadol metabolites. When the oxygen is 
demethylated a fragment of m/z 58.0665 is produced, while the demethylation of 
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nitrogen generates a fragment of fragment of m/z 44.0498. Therefore, it can be 
concluded that the incubation conditions and detection parameters are favourable for 
the generation of demethylated metabolites including those with the same chemical 
formula but with different retention times.  
4.3. JHW18: Identification of the parent compound  
The presence of parent JWH18 (C24H23NO) was confirmed. LC-QTOF-MS extract 
of chemical formula returned a result of a compound with an M+1 value of m/z 
342.1841. The chromatogram in Figure 4.3.1 shows the elution of a compound at 




Figure 4.3.1 Chromatogram obtained of incubation mixtures containing parent 
JWH18.  
The library spectra of parent JWH18, (see Appendix), displays fragment ions of m/z 
324.1852, 214.1226 and 155.0491 at 10V. At 20V there is an additional fragment of 
m/z 127.0542 and at 40V, a fragment of m/z 43.0542. The mass spectra obtained for 
this sample, Figure 4.3.2, displays a similar fragmentation pattern, again confirming 
the presence of the compound in this mixture.  
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Figure 4.3.2 Mass spectra of parent JHW18 from incubation mixtures, displaying 
the same fragment ions as the library spectra. 
 
The major ions have an m/z of 214.1221, 155.0490, 217.0541 and 43.0545. The 
parent compound (M+1) had an m/z of 342.1843. The theoretical mass of parent 
JWH18, according to the PCDL library, is only 3ppm different (342.1852), 
consistent with this compound. 
4.4 Monohydroxylated JWH18 
It is known that one of the most readily detectible metabolites of JHW18 is the 
monohydroxylated form of the drug (C24H23NO2)
(43)
. A compound with an M+1 of 











Figure 4.4.1 Chromatogram of monohydroxylated JWH18.  
Importantly, the chromatogram features three partially resolved peaks, suggesting 
the monohydroxylation process can occur at three sites on the molecule. The mass 
spectra obtained after MSMS for the compound eluting at 8.9 minutes is displayed in 
Figure 4.4.2.  
Figure 4.4.2 Mass spectra after MSMS of monohydroxylated JWH18 obtained after 
8.9 minutes.  
 
At 10V and 20V the spectra indicates the m/z of the parent ion to be 358.1796, 
15.9953 mass units greater than the m/z of the parent compound, consistent with 
hydroxylation. It appears that some parts of the molecule remian unaltered, as 
fragments of m/z 155.0490 and 127.0522 are retained in the spectrum. Of note is a 
fragment ion of m/z 230.1123, 15.9902 mass units greater than 214.1121, consistent 
with hydroxylation. Accordingly, the potential sites of JWH18 hydroxylation which 
generate these characteristic fragments are inferred according to the Figure 4.4.3. To 












Figure 4.4.3 Proposed fragmentation and monohydroxylation of JWH18 at three 
suggested sites(43).  
 
The presence of three peaks in the chromatogram suggests that three MSMS spectra 
should be obtained for the unique retention time of each peak. Evidentially, only one 
chromatogram was extracted. Where multiple peaks have the same m/z value (as is 
the case here), the data needs to be manually extracted because at times MSMS data 
is only generated for the selected peak.  This requires the data to be sorted by 
retention time, where the MSMS data can then be generated according to retention 
time after it is confirmed that the mass of the parent ion in the generated MSMS 
spectra has the correct m/z value. Manual extraction of the data was not carried out 
due to time constraints.  
The detection of monohydroxylated metabolites of JWH18 in post-incubation 
mixtures confirms the capacity of the S9 preparation to generate hydroxylated 
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metabolites in vitro, and suggests that it is a suitable source of monooxygenases for 
the potential Phase I hydroxylation of 25H-NBOMe, if such metabolites are 
characteristic of its biotransformation. Furthermore, the demonstrated capacity of the 
S9 preparation to catalyse Phase I demethylation and dehydrogenation reactions, 
indicates that a suite of Phase I enzymes is active within the preparation(43).  
4.5 Incubation time 
The peak areas of tramadol and JWH18 and their relevant metabolites were obtained 
after separate incubations of both one and three hours. Table 4.5 illustrates the 
average peak area of each metabolite obtained in each test after two replicates.  
Table 4.5 Average peak area of tramadol and JHW18 metabolites obtained after 1 
and 3 hours incubation.  
 
 
The table illustrates that for each metabolite, the peak area of the compound was 
greater after 3h than 1h of incubation. A 3-fold increase from 1h to 3 h was observed 
in demethylated tramadol. For monohydroxylated and dehydrogenated JWH18 the 
longer incubation time produced a 4 and 3-fold increase in metabolites, respectively.  
Metabolite  1h 3h Fold increase 
in metabolites 














161489  656673  3  
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As expected, with increasing incubation time more metabolite was generated. Taking 
account of the limited number of replicates, the peak areas of the metabolites 
generated were approximately three times greater after 3h than 1h. There was 
reasonable linearity in the production of metabolites over the 3h incubation time.  
Short incubation times, such as one hour, are predominantly used in metabolic 
studies due to increasing enzyme instability with increased incubation time(44). In 
most systems used for in vitro metabolic studies, such as those conducted with 
hepatocytes or liver microsomes, a reaction rate plateau is reached within one hour 
of incubation time. Furthermore, as the objective of the investigations described in 
this thesis was to achieve a qualitative assessment of the metabolites produced, 
rather than a quantitative one, it was deemed that sufficient product was generated 
within a1h incubation and, as a consequence, this incubation time was adopted for all 
future experiments.  
4.6 Effect of enzyme concentration  
To optimise the amount of enzyme present to ensure maximum production of the 
metabolite in the 1h incubation, the effect of enzyme concentration on metabolite 
production was investigated. The graph constructed after the peak areas of each 
compound was obtained (via average of two replicates) is displayed in the Figure 





Figure 4.6 Effect of enzyme concentration on the rate of metabolite production from 
25H-NBOMe over a 1h incubation time.    
 
The production of both compounds appears to be linear up to 200 μg until somewhat 
of a plateau is reached. Consequently, to ensure that the rate of metabolite 
production was not limited by enzyme concentration, 400μg of protein (20μL S9) 
was chosen for all future experiments.  
4.7 Extraction efficiency  
To maximise the extraction of the parent drug and its metabolites from the 
incubation mixtures, the effect of multiple extractions with ethyl acetate was 








Table 4.7 Extraction efficiency: Percentage recovery of parent 25H-NBOMe 
following one, two, three and four extractions  






Maximum recovery was obtained after 2 sequential extractions, each with 600μL of 
ethyl acetate. Anomalous results were obtained for those incubation mixtures 
subjected to three or four extractions (Table 4.7). This illustrates that variability 
appears to be inherent in extraction efficiency, between individual incubation 
mixtures. 
In general, it is desirable for extractions to recover 80% of compounds produced. It 
is evident in this case that approximately 20% less than this ideal efficiency was 
achieved. As using two pooled extractions only provided a 7% increase in recovery, 
a single extraction was used in all future experiments to save time and reagents. It is 
also assumed that the 25H-NBOMe metabolites are extracted with similar efficiency 
to that of the parent compound. Given that ethyl acetate functions as a generically 
useful extraction solvent for compounds of this type, and given that the purpose of 
this investigation was qualitative rather than quantitative, this assumption was 
considered acceptable. The recovery of the hydroxylated and demethylated 
metabolites will differ slightly because they differ slightly in polarity, and in turn 
this recovery will also differ slightly from the parent compound. Small variations in 
the recovery of the metabolites is considered acceptable due to the qualitative nature 
of this investigation.  
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 For future investigations, especially if one of the experimental aims was to quantify 
the amount of metabolite produced, an alternative extraction method should be 
investigated. This may include the use of an alternative solvent, such as 
acetonitrile(41). In vitro metabolism studies such as that conducted by Gandhi et al. 
(2014) involved the use of acetonitrile to extract metabolites after incubation of 
synthetic cannabinoids with human liver microsomes.(41). Additionally, there were 
two variables the experiment in this thesis, the first being multiple extractions, and 
the second being separate extraction. There should have been one variable only.  
Alternatively to the use of a separate incubation for each of the numbers of 
extractions being investigated, simply use one incubation mixture; extract it once 
with 600 μL of ethyl acetate, separate the organic and inorganic phases and remove 
the organic phase for analysis. Then re-extract the same aqueous phase a second time 
with another 600 μL of ethyl acetate, remove the organic phase place it in a second 
tube and extract for a third time and then a fourth time. The amount of drug in each 
of the four ethyl acetate extracts should then be analysed. Adding the ethyl acetate 
together from 2, then 3 and then 4 extractions gives the complete information on the 
recovery efficiency. The experiment should be repeated in triplicate to show 
variability.  
25H-NBOMe metabolism  
4.8 25H-NBOMe: Identification of parent compound  
In assays of the incubation mixtures, the unmetabolised 25H-NBOMe (C18H23NO3) 
was identified in chromatograms by searching for the m/z value corresponding to its 
expected M+1 (302.1756, see appendix). The chromatogram in Figure 4.8 confirms 





Figure 4.8.1 Chromatogram of parent 25H-NBOMe obtained from incubation 
mixtures.  
 
The library mass spectrum of 25H-NBOMe shows that mass spectrometry of the 
compound produces fragments with m/z values of 91.0544, 121.0642, The latter ion 
is the parent ion of m/z 302.1756 (M+1) of the compound. The same fragments 
where found to be associated with a compound extracted from the incubation 
mixtures is shown in Figure 4.8.2.  
Figure 4.8.2 Mass spectra of parent compound obtained from incubation mixtures 




Figure 4.8.2 illustrates the presence of the key 25H-NBOMe fragments. The M+1 of 
the parent ion is 302.1740 at 10V. The key fragment ions are also present, being 
121.0651 and 91.0546 in the sample. Therefore, the fragmentation of the parent 







Figure 4.8.3 Predicted fragmentation of 25H-NBOMe derived from interpretation of 
its mass spectra.  
 
4.9 Demethylated 25H-NBOMe 
Previous studies of NBOMe variants have identified one of the major Phase I 
metabolites to be demethylated forms of the parent drug(13). Consequently, data was 
analysed for the formula C17H21NO3. This compound was identified 
chromatographically in the mixture with three peaks, shown to have a retention time 
of 6.8, 8.2 and 8.8 mins.  
Figure 4.9.1 Chromatogram of demethylated 25H-NBOMe obtained from 




The three peaks in the chromatogram suggests three possible sites of demethylation. 
Figure 4.9.2 displays the MSMS spectrum obtained after 6.9 minutes.  
Figure 4.9.2. Mass spectra of demethylated 25H-NBOMe correlating to the peak 
obtained at 6.9 minutes.  
 
Figure 4.9.4 shows that the M+1 value of the compound is m/z 288.1584. This value 
is 14.0156, a mass difference consistent with the demethylation process. As seen in 
the spectrum the fragments 121.0651 and 91.0546 remain unchanged from that of the 
parent compound. Accordingly, the sites of demethylation can be hypothesised 





Figure 4.9.3. Proposed demethylation sites of 25H-NBOMe.  
Figure 4.9.3 shows that demethylation on the second or fifth oxygen gives rise to 
two possible isomers of demethylated 25H-NBOMe, accounting for two of the peaks 
in the chromatogram, and the unchanged m/z of the 121.0651 and 91.0546 ions in 
the spectrum from the demethylated sample, compared to that of the parent.  
According to the inferred site of demethylation, these metabolites are named 2-
demethyl NBOMe and 5-demethyl NBOMe. Synthesis and LC-QTOF-MS analysis 
of each isomer and comparison of their retention times and mass spectrum would 
confirm which isomer(s) is present and thus the exact location of demethylation.  
Previous studies of other NBOMe variants, such as that  on 25C and 25I-NBOMe, 
have found that the fragment ion of m/z 91 predominately remains unchanged, 
meaning it is most likely that the left side (as it has been drawn in Figure 4.9.5; the 
benzene ring) of the molecule is the site of demethylation(13). Additionally for this 
data set, the QTOF data is once again required to be manually extracted to obtain the 
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mass spectra for each peak to completely analyse the sample and the potential sites 
of demethylation.  
4.10 25H-NBOMe hydroxylation  
Similarly, monohydroxylation 25H-NBOMe (C18H23NO4) was expected to generate 
an M+1 value corresponding to the addition of 16 mass units compared to that of the 
parent. The chromatogram in Figure 4.10.1 illustrates the chromatogram obtained for 
a compound of this chemical formula with an M+1 value of 318.1701.  
 
Figure 4.10.1 Chromatogram of suspected hydroxylated metabolites of 25H-
NBOMe obtained from incubation mixtures.  
 
The chromatogram features five peaks at retention times of 6.5, 6.9, 7.2, 7.5 and 8.8 
minutes, suggesting that there are four isomers of this compound, and four possible 
sites of 25H-NBOMe hydroxylation. The mass spectra in Figure 4.10.2 was obtained 
following MSMS of the compound at a retention times of 7.1 minutes.  
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Figure 4.10.2 Mass spectra of hydroxylated 25H-NBOMe.  
The m/z of the parent ion is 318.1701 at 10V, 15.9959 mass units greater than that of 
the parent compound, consistent with the addition of an oxygen associated with 
hydroxylation. A site of hydroxylation is suggested by the m/z (137.0596) of the 
major ion visible at both 10 and 20V. A further potential site of hydroxylation is 
suggested by the m/z (107.0495) of the dominant ion at 40V. These ions are 15.9945 
and 15.9940 mass units greater than their respective non-hydroxylated fragments 
(121.0651 and 91.0546).  
Once again, due to time constraints, the expected number of mass spectra (four) was 
not obtained because the data needs to be manually extracted for each retention time. 
Interpretation of the spectrum in Figure 4.10.2 allows the fragmentation pattern and 





Figure 4.10.3 Proposed sites of hydroxylation of 25H-NBOMe.   
Figure 4.10.3 shows that it is possible for any carbon in the NBOMe ring to be 
hydroxylated, thus giving rise to the characteristic ions of 137.0596 and 107.0495 for 
the compound. Therefore, the hydroxylated metabolites may be 3-hydroxyNBOMe, 
4-hydroxyNBOMe, 5-hydroxyNBOMe or 6-hydroxyNBOMe.  
Investigation of Phase II metabolism of 25H-NBOMe  
4.11 Acetylation 
Having confirmed the presence of the demethylated metabolite in incubation 
mixtures supplemented with acetyl CoA, a search was performed for an acetylated 
derivative (C19H23NO4), potentially generated by the Phase II enzymatic addition of 
an acetyl group (CH3CO) to the hydroxyl moiety generated by demethylation. Such a 
product would be expected to produce an M+1 with an m/z of 329, approximately 42 
mass units greater than the unacetylated product. A search for this compound by 
formula yielded no result, and no compound with the relevant M+1 value was found. 
This suggested that acetylation of the demethylated metabolite did not occur.  
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Similarly, a search for an acetylated hydroxylated compound failed to yield a result.  
In this case, the acetylated derivative (C20H25NO5) would be expected to generate an 
M+1 with an m/z value of approximately 360. This compound was not found by 
either a search according to chemical formula or by m/z value, and it was concluded 
that acetylation of the hydroxylated metabolite did not occur.  
4.12 25H-NBOMe Glucuronidation  
Glucuronidated forms of the Phase I metabolites would be expected to generate a 
product of 176 mass units greater than the corresponding Phase I metabolite due to 
the enzymatic addition of a C6H8O6 group. A glucuronide derived from a 
demethylated metabolite would, therefore, have the formula of C23H29NO9. This 
compound would have an M+1 m/z value of 464. As no compound with this formula 
or m/z value was found, it can be concluded that glucuronidation of the demethylated 
metabolite did not occur.  
For the hydroxylated metabolite, the glucuronide derivative would have the formula 
C24H31NO10. Accordingly, this compound would generate an M+1 with an m/z of 
494, which, again, was not found.  
4.13 25H-NBOMe Sulfation 
The presence of both demethylated and hydroxylated metabolites was confirmed in 
incubation mixtures containing PAPS, and a search for Phase II sulfate conjugates 
was conducted. These products will have an m/z 64 mass units greater than the 
relevant Phase I metabolite due to the enzymatic addition of SO3
-. 
The sulfate conjugate of the demethylated metabolite (C17H21NO6S) would generate 
an M+1 with an m/z of 368. Again, a search via chemical formula and m/z value 
returned no result. Similarly, the sulfate conjugate of the hydroxylated metabolite 
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(C18H23NO7S) with an M+1 m/z value of 398 was not detected and no evidence of 
the process of sulfation was found. 
4.14 Search for Phase II conjugating enzymes   
As glucuronides of the 25H-NBOMe metabolites where not detected in incubation 
mixtures supplemented with UDP glucuronic acid, experiments were conducted to 
ascertain whether the appropriate conjugating enzyme, UDP glucuronyl transferase, 
was present in the S9 preparation.  
To investigate this possibility, paracetamol (C8H9NO2), which is known to undergo 
glucuronidation, was incubated with UDP glucuronic acid and S9 at 37° for 1 hour. 
The incubation mixture was extracted with ethyl acetate according to the usual 
protocol and a search was carried out for paracetamol glucuronide (C14H17NO8; M+1 
m/z 328) in the extract.  
Unmetabolised paracetamol (M+1 m/z 152.1680) was detected in the extract eluting 
at a retention time of 1.759 minutes (Figure 4.14). 
Figure 4.14 Chromatogram of parent paracetamol displaying a well resolved, bell-
curved shaped peak, confirming the presence of parent paracetamol.  
 
However, a search for paracetamol glucuronide (C14H17NO8) did not return a result. 
No compound was detected with an m/z of 328.1680, the expected mass of the M+1 
indicating that either glucuronidation of paracetamol did not occur, or the 
paracetamol glucuronide was not detected. The issue of detection is further discussed 
in 4.15.  
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4.15. Failure to produce or detect Phase II metabolites of 25H-NBOMe  
Phase II metabolism of 25H-NBOMe was not demonstrated in the preliminary 
investigations described in this thesis. This may be due to the absence of soluble 
enzymes required to catalyse the conjugation of the activated compound with the 
xenobiotic.  
The activation of the conjugating compounds Acetyl CoA, UDP-glucuronic acid and 
PAPS has been explained in detail in Chapter 1. These were compounds added to the 
incubation mixtures, and are thus already activated. This being the case, the 
requirement for the activating enzymes of Acetyl CoA Synthetase, UDP glucose 
pyrophosphorylase, UDP glucose dehydrogenase and ATP is bypassed.  
4.16 Absence of soluble enzymes required to catalyse the conjugation of the 
activated compound with the xenobiotic 
As activated conjugating compounds (Acetyl CoA, UDP-glucuronic acid and PAPS) 
were added to the incubation mixtures in an attempt to identify Phase II conjugates, 
it is most likely that failure to detect them was due to the absence of the conjugating 
enzymes in the S9 preparation. Alternatively, but unlikely given the known 
metabolism of other NBOMe variants, it is possible that the parent drug may not be 
receptive to conjugation. 
(a) Phase II Acetylation 
The enzymes responsible for catalysing the conjugation of the activated acetate 
to the xenobiotic are termed “acetyltransferases”(45). These soluble enzymes are 
located in the cytosol. Both O-Acetylation and N-Acetylation are common 
processes in phase II metabolism(45). N- acetyltransferases (NATs) have been 
shown to be involved in the Phase II metabolism and identified as enzymes 
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active in the phase II metabolism of 2C compounds (psychoactive 
phenethylamines which feature methoxy groups on positions 2 and 5 of the 
benzene ring) such as 25H-NBOMe. There are two isoforms of NATs, NAT1 
and NAT2. Being expressed in the liver and intestinal epithelium, NAT2 
enzymes are of relevance here(45). However, though acetyl CoA was added to the 
incubation mixtures in an attempt to identify potential Phase II metabolites, 
neither O nor N-acetylated conjugates were detected. This may be due to the 
absence of acetyltransferases in the S9 fraction, preventing the transfer of the 
acetyl group to either the demethylated or hydroxylated metabolites of 25H-
NBOMe (Figure 4.16a).  
 
 
Figure 4.16a Potential acetylation site of the demethylated metabolite of 25H-
NBOMe. This conjugate was not detected.   
 
(b) Phase II Glucuronidation  
Similarly, despite UDP glucuronic acid being added to the incubation mixtures in 
an attempt to identify Phase II metabolites, glucuronide conjugates where not 
detected. This may also have been due to compromised incubation conditions 
due to the absence of conjugating enzymes.  
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Predominantly expressed in the liver, UDP-glucuronosyltransferases (UGTs) 
catalyse a process which transfers a glucuronate moiety from UDP glucuronic 
acid to an oxygen, carbon or nitrogen atom in the xenobiotic or it’s Phase I 
metabolites. The addition of the polar glucuronic acid produces a hydrophilic 
conjugate which can then readily be excreted (Figure 4.16b)(46).  
 
Figure 4.16b Potential glucuronidation site of the demethylated metabolite of 25H-
NBOMe. The conjugate was not detected.  
 
It was expected that UDP-glucuronosyltransferases would be expressed in the S9 
preparation. Being transmembrane proteins, expressed particularly in the nucleus and 
smooth endoplasmic reticulum of hepatocytes, it is logical to expect that in the 
homogenisation of hepatocytes to generate the S9, these enzymes would be 
present(46).   
(c) Paracetamol glucuronidation  
The apparent failure of paracetamol metabolism introduces the idea that, instead of 
an absence in the system to carry out Phase II metabolism, it may be that the 
instrumental parameters or incubation conditions are not favourable for the detection 
of these metabolites, making it appear as though they have not been formed. 
Paracetamol is a known to undergo glucuronidation and that it enzymatically reacts 
with UDP glucuronic acid to produce a paracetamol glucuronide, unlike 25H-
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NBOMe(42).  If the enzymes and substrates required to facilitate glucuronidation 
where present, the paracetamol glucuronide will have been detected. Failure to detect 
may been due to the very early elution time, of less than one minute and therefore 
outside the ability of the QTOF to detect such an early eluting compound.  
 The addition of a glucuronide group increases the polarity of any compound (the 
same can be said relating to the processes of acetylation and sulfation). The highly 
polar nature of the compound reduces its affinity for the chromatography column, 
reducing its retention time(46). This may in turn compromise the way in which the 
compound reaches the mass analyser and is detected, giving the illusion of failed 
glucuronidation. Time and budgeting did not allow for further investigation into 
changing the incubation conditions or instrumental parameters to improve 
glucuronide detection.  
(d) Phase II sulphation  
Although PAPS was added to the incubation mixtures in order to identify a third 
possible Phase II conjugate, sulfate conjugates where not detected. It can be inferred 
that the transfer of a sulphate group from PAPS to demethylated and hydroxylated 
25H-NBOMe is not facilitated by the enzymes present in the S9. One would expect 
the action of sulphotransferases (SULTS) to carry out the process of sulphation.  










Figure 4.16d Potential site of sulphation of the demethylated 25H-NBOMe 
metabolite. This conjugate was not detected.  
  
Sulphotransferases, being cytosolic enzymes of the liver, are expected to be present 
in S9 preparations. However, no evidence for the generation of sulphate conjugates 
was found in these incubation mixtures containing 25H-NBOMe and PAPS (47).  
SULTs are known to be susceptible to substrate inhibition in vitro. This arises from 
the conformational change that occurs when the substrate binds to the active site of 
the enzyme, reducing the ability of the enzyme to catalyse sulphation(48). This may 
have been a compromising factor.  
Previously discussed in the introduction, the CYP450 group of enzymes is another 
group of enzymes whose expression and action in dominant in drug metabolism. One 
may consider the possibility of reduced CYP450 activity the reason behind why the 
activated compounds where not conjugated to the Phase I metabolite, meaning that 
the amount of demethylated and hydroxylated metabolite may be too small to 































5.1 Enzyme profiling studies  
It is known that S9 contains both microsomal and cytosolic cellular components, and 
as a result should yield a greater metabolic profile than other in vitro means of 
studying hepatic metabolism, given that it contains the entire spectrum of hepatic 
enzymes. This is in comparison to the other methods of in vitro hepatic study by the 
use of human liver microsomes, in which incubation mixtures are required to be 
supplemented with both conjugating enzymes and reaction substrates (46). Thus far, 
the cause of the absence of Phase II metabolism has been speculated, the focal point 
being the potential lack of enzyme presence or activity. However, it would be 
pertinent to profile the enzymes of S9 to find out exactly what is required to be 
added to the system in order to induce metabolism, rather than speculating on what, 
in theory, should be present and adding reagents accordingly.  
There have been multiple studies carried out to profile the exact identity of the 
enzymes present in HLMs and other hepatic study methods. It being evident that the 
CYP450 enzymes active in Phase I metabolism are present in the S9, it would be 
pertinent to investigate the presence of enzymes relevant to Phase II metabolism, by 
an alternative method than drug incubation, which assumes the presence of the 
enzymes.  
Terai et al. (2012) developed a luminescent probe for the detection of NATs and its 
activity within cells. A probe specific to the genetic sequence of NAT1 and NAT2 
type enzymes containing a Tb3+ group and an aniline moiety was synthesised and 
incubated separately with both pigeon liver and human liver cytosol. When the probe 
binds to the substrate, photoinduced electron transfer occurs between the alanine 
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moiety and the Tb atom, inducing luminescence detectable in the near Infra-Red 
region(49). This luminescence was detected in assay supplemented with Acetyl CoA, 
thus leading to the conclusion that the enzymes required for acetylation where 
present. A similar method could be employed to detect the level of activity of NATs 
in S9. Increased luminescence infers increased enzyme, as an increased amount of 
probe is able to bind to the increased amount of enzyme, inducing increase electron 
transfer and therefore emission of light(49). The luminescence produced for the S9 
could be compared to that in hepatocytes, liver cytosol, and microsomal preparation, 
to gain an understanding of the difference in enzyme content between them.  
It is recommended that profiling with the same method be carried out in a similar 
manner to test for the presence of UGTs and SULTs. If the amount of enzyme 
activity in S9 can be estimated, this information can be used to derive what is 
required to be added into the S9 incubation regarding the amounts of substrate and 
enzyme, to increase the chances of inducing Phase II metabolism.  
5.2 Improving the detection of Phase II conjugates  
It is possible that the enzymes are present and the detectability of the Phase II 
conjugates are compromised. A means of confirming if this is the case it to use a 
method similar to that implemented by Wohlfarth et al. (2016). Studying the 
metabolism of 25C and 25I-NBOMe, possible metabolites of each compound where 
synthesised to create reference standards to which the metabolites detected in human 
and mouse urine, as well as incubation with human hepatocytes, could be 
compared(46). Demethylated, hydroxylated, acetylated, glucuronidated and sulfated 
potential metabolites where synthesised and diluted in methanol to produce a 
reference standard of 10μg/ml. These were subject to LC-QTOF-MS in the same 
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way as the extracts from the urine and hepatocyte samples, with the same mobile 
phase and flow rate. The conditions for the gradient elution where slightly different 
as the percentage of each mobile phase and the time at which each was held was 
altered to favour detection of the synthesised compounds(46).  
These metabolites, both the reference standards and naturally produced metabolites, 
eluted between six and eleven minutes. Evidentially, the parameters used in this 
study facilitated the detection of metabolites, and the identity of the metabolites 
formed in hepatocyte incubations could be confirmed via reference to these 
standards. Therefore, it is recommended that a similar method be employed for 
future studies of 25H-NBOMe. The same could be said for paracetamol in its use as 
a means of investigating the presence of Phase II enzymes. In future work it would 
be recommended to obtain a synthesised paracetamol glucuronide, such as 
Paracetamol β-D glucuronide, available from Sigma Aldrich. If this can be detected 
using the same LC-QTOF-MS conditions as those used for the incubation assays, it 
can be concluded that detection of the Phase II metabolites is possible. If not, 
changes can be made to improve such detection.  
5.3 Comparison of this investigation to other studies  
There have been multiple studies relating to the metabolism of different NBOMe 
type drugs, which corroborate the findings found in this investigation, particularly 
regarding Phase I metabolism. Wohlfarth et al. (2016) found, from incubation of 
hepatocytes with human hepatocytes, demethylated, hydroxylated, glucuronidated 
and sulfated 25C-NBOMe metabolites. It was found that the methoxy groups where 
demethylated, as with 25H-NBOMe. Similarly, hydroxylation was confined to the 
NBOMe ring in both studies(13).  
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The same metabolites where found following the incubation of hepatocytes with 25I-
NBOMe.  The demethylated and hydroxylated Phase I metabolites where 
dealkylated, glucuronidated and sulfated as part of Phase II metabolism(13). Thus, it 
can be stated that the Phase I metabolite profiling of this investigation was conducted 
with success, as it produced similar results to those found in studies of other NBOMe 
variants. However, questions pertaining to absence of Phase II metabolism in this 
investigation remain. Phase II metabolites where detected by Wohlfarth et al., but 
where not detected in this investigation.  
It is possible that use of S9 is not the most efficient means of studying metabolism in 
the liver. Given the success of other studies, it is recommended that further 
qualitative studies of 25H-NBOMe metabolism utilises an alternative means of in 
vitro liver preparation. This may be through the use of human liver microsomes, 
where the conjugating enzymes and necessary substrates are added to the incubation 
mixtures, ensuring each is present in sufficient concentration to form Phase II 
conjugates(21). Additionally, administration to Wistar rats is also recommended, as an 
in vivo model. This involves administration of the drug to the animals, and 
consequently examining their faeces and urine for the presence of metabolites. For 
years the administration of xenobiotics to rats has been utilised, however, ethical and 
financial considerations exist due to the cost of obtaining the rats, ethical approval, 
and the extra resources required with keeping live animals(13).  
Moreover, manual extraction of MSMS data may reveal the presence of the required 





5.4 Significance of this study  
This investigation of the metabolism of 25H-NBOMe is two-pronged. Firstly, 
valuable information has been obtained relating to the Phase I metabolism of 25H-
NBOMe. Not only have two major Phase I metabolites been identified; this being the 
demethylated and hydroxylated forms of the parent compound, but the characteristic 
fragmentation pattern of each was obtained. In forensic toxicology, where chemical 
analysis such as LC-QTOF-MS is used, it is very important for the relevant m/z 
values, to 4dp, of compounds to be identified, so they can be used for reference 
against samples of unknown identity. Here, the m/z of 288.1584 was identified for 
the demethylated metabolite, and 318.1707 for the hydroxylated metabolite. As 
previously discussed, there were conclusions reached regarding the location on the 
compound of these particular metabolic processes.  
It is important for forensic science laboratories to obtain this information pertaining 
to any kind of drug, particularly regarding novel drugs. With new variants of novel 
drugs being constantly developed, the practise of identifying their metabolites is 
important to facilitate their identification in toxicological screening. In the future, 
this can lead the way for studies to be carried out which corroborate the findings of 
this investigation and synthesis of reference standards for novel drugs and their 
metabolites to facilitate their identification with greater precision and certainty.  
Perhaps of even greater importance than metabolite identification, is what has been 
learned regarding the methods used to study drug metabolism. The use of S9 is 
relatively recent in comparison to the use of HLMs, cryopreserved hepatocytes, urine 
studies and the use of administration to rats. Much has been speculated relating to, in 
theory, what should be present in the S9 fraction after processing. However, it 
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appears that it would be pertinent to carry out work to identify the presence of 
required enzymes in S9 to confirm whether or not it would be likely to facilitate 
Phase II metabolism. From here the relevant reagents can be added to produce a 
successful metabolism profile. The work from this study can be further investigation 
to produce a sound procedure for the use of S9 in metabolism studies, which would 
be advantageous due to the fact that S9 is easily obtained and stored, and does not 
require processing with multiple other reagents, as does the use of HLMs and 
hepatocytes.  
Additionally, this study highlights the difference between qualitative and quantitative 
studies. Altered incubation times and extraction procedures and well as changes in 
software analysis would improve the recovery of the compounds and also knowledge 
pertaining to its activity over an extended period of time, indicative of what may 
occur after an extended time post ingestion by a user. The simple identity of Phase I 
metabolites and suggested alterations to the S9 method, pave the way for 
improvements to be made and the use of reference standards which can be used in 
quantitative studies. This being a preliminary study, the results focus on metabolite 
generation. Further studies can take this method and apply it to reference standards 
to identify the retention times and particular fragmentation of isomers, as well as 
application of 25H-NBOMe in a quantitative manner.  
In conclusion, the identity of Phase I 25H-NBOMe metabolites, and the foundations 
of the investigation into the use of S9 to study xenobiotic metabolism, has been 
successfully carried out. The future of such studies will be a refining of the 
techniques used to create successful Phase II metabolism, and to extend knowledge 
of 25H-NBOMe in quantitative studies to increase knowledge of its metabolism in 
vivo.   
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